Interleukin-17A (IL-17A): A silent amplifier of COVID-19.
COVID-19
Cytokine storm
IL-17A
Immunotherapy
Th17
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
20
05
2021
revised:
21
07
2021
accepted:
26
07
2021
pubmed:
8
8
2021
medline:
28
9
2021
entrez:
7
8
2021
Statut:
ppublish
Résumé
One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. Emerging evidence has identified a potential link between elevated interleukin-17A (IL-17A) levels and disease severity and progression. Considering that per se, IL-17A can activate several inflammatory pathways, it is plausible to hypothesize an involvement of this cytokine in COVID-19 clinical outcomes. Thus, IL-17A could represent a marker of disease progression and/or a target to develop therapeutic strategies. This hypothesis paper aims to propose this "unique" cytokine as a silent amplifier of the COVID-19 immune response and (potentially) related therapy.
Identifiants
pubmed: 34364043
pii: S0753-3322(21)00762-9
doi: 10.1016/j.biopha.2021.111980
pmc: PMC8318692
pii:
doi:
Substances chimiques
Biomarkers
0
Inflammation Mediators
0
Interleukin-17
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111980Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Références
Arthritis Res Ther. 2004;6(6):240-7
pubmed: 15535837
Autoimmun Rev. 2020 Jul;19(7):102567
pubmed: 32376392
Crit Care. 2020 Jul 27;24(1):463
pubmed: 32718345
Clin Exp Immunol. 2002 Mar;127(3):539-46
pubmed: 11966773
N Engl J Med. 2021 Apr 22;384(16):1503-1516
pubmed: 33631066
Clin Rev Allergy Immunol. 2018 Dec;55(3):379-390
pubmed: 30109481
Autoimmun Rev. 2020 Jul;19(7):102572
pubmed: 32376393
J Immunol. 2000 Nov 15;165(10):5814-21
pubmed: 11067941
Biosci Rep. 2019 Feb 8;39(2):
pubmed: 30655311
J Immunol. 1998 Dec 1;161(11):6383-9
pubmed: 9834129
Mediators Inflamm. 2014;2014:590409
pubmed: 24692851
Nat Rev Immunol. 2020 Jun;20(6):345-346
pubmed: 32358580
Biochem Pharmacol. 2009 Mar 1;77(5):878-87
pubmed: 19073154
Autoimmun Rev. 2020 Dec;19(12):102695
pubmed: 33130000
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Autoimmun Rev. 2020 Jul;19(7):102569
pubmed: 32376394
Pediatr Neonatol. 2020 Jun;61(3):364-365
pubmed: 32317217
Cell Prolif. 2021 May;54(5):e13024
pubmed: 33751722
J Invest Dermatol. 2014 Dec;134(12):2990-2993
pubmed: 24999591
Autoimmun Rev. 2020 Jul;19(7):102562
pubmed: 32376400
Biochem Pharmacol. 2010 Feb 15;79(4):525-34
pubmed: 19765545
Nat Commun. 2020 Jul 6;11(1):3434
pubmed: 32632085
Br J Clin Pharmacol. 2021 Mar;87(3):1578-1581
pubmed: 32627226
Int Immunopharmacol. 2021 Jan;90:107225
pubmed: 33302033
Nature. 2008 Jul 17;454(7202):350-2
pubmed: 18469800
Arthritis Res Ther. 2003;5(4):R186-92
pubmed: 12823853
Nat Rev Drug Discov. 2012 Oct;11(10):763-76
pubmed: 23023676
Front Immunol. 2018 Nov 30;9:2752
pubmed: 30555461
Cytokine Growth Factor Rev. 2003 Apr;14(2):155-74
pubmed: 12651226
Parasite Immunol. 2017 Apr;39(4):
pubmed: 28207936
Med Hypotheses. 2020 Nov;144:109935
pubmed: 32795834
Nat Rev Rheumatol. 2019 Aug;15(8):491-501
pubmed: 31227819
Ann Oncol. 2020 Jul;31(7):961-964
pubmed: 32247642
Dermatol Ther. 2020 Jul;33(4):e13580
pubmed: 32406078
Arthritis Res Ther. 2004;6(2):R120-8
pubmed: 15059275
Comp Med. 2009 Dec;59(6):517-26
pubmed: 20034426
Rheumatol Int. 2020 Oct;40(10):1707-1716
pubmed: 32591970
Nat Rev Rheumatol. 2015 Jul;11(7):415-29
pubmed: 25907700
Front Pharmacol. 2016 Aug 11;7:250
pubmed: 27561214
Immunol Res. 2006;34(3):229-42
pubmed: 16891673
J Immunol. 2008 Oct 15;181(8):5183-8
pubmed: 18832668
J Microbiol Immunol Infect. 2020 Jun;53(3):368-370
pubmed: 32205092
Immunity. 2020 May 19;52(5):731-733
pubmed: 32325025
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
Curr Rheumatol Rep. 2021 Apr 24;23(5):31
pubmed: 33893896
Cell Mol Immunol. 2010 May;7(3):164-74
pubmed: 20383173
Med Hypotheses. 2020 Jul;140:109749
pubmed: 32339777
J Immunol. 2020 Aug 15;205(4):892-898
pubmed: 32651218
J Med Internet Res. 2020 Aug 13;22(8):e20193
pubmed: 32707537
Autoimmun Rev. 2014 Jun;13(6):668-77
pubmed: 24418308
J Inflamm Res. 2021 Feb 03;14:253-263
pubmed: 33568930
Blood Adv. 2020 Apr 14;4(7):1307-1310
pubmed: 32243501
Pharmacol Res. 2020 Jun;156:104791
pubmed: 32302707
Ann Rheum Dis. 2012 May;71(5):768-76
pubmed: 22258491
Viruses. 2021 Feb 03;13(2):
pubmed: 33546489
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Autoimmun Rev. 2020 Jun;19(6):102538
pubmed: 32268212
Expert Opin Biol Ther. 2020 Aug;20(8):829-830
pubmed: 32510244
J Immunol. 1999 Jan 1;162(1):494-502
pubmed: 9886425
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Leukoc Biol. 2021 Jan;109(1):73-76
pubmed: 33289169
J Immunol. 1998 Apr 1;160(7):3513-21
pubmed: 9531313
Biochem Biophys Res Commun. 2011 May 20;408(4):658-62
pubmed: 21530487
J Exp Med. 1996 Jun 1;183(6):2593-603
pubmed: 8676080